Table 5.

Proportion of non-deteriorated patients (Full Analysis Set, n  = 80)

	Placebo ( n  = 19)	PXT3003 LD ( n  = 21)	PXT3003 ID ( n  = 21)	PXT3003 HD ( n  = 19)	HD versus Placebo		HD versus PLI
Non-deteriorated	10 (52%)	10 (48%)	9 (43%)	15 (79%)	Relative Risk	P-value	Relative Risk	P-value
					1.5 (1.03;1.77)	0.047*	1.66 (1.24;1.93)	0.010*

Data are count (%) of non-deteriorated patients per group and Relative Risks (90% CI) for the HD group versus Placebo and versus PLI assessed with a logistic regression model. P-values are one-tailed. *P < 0.05.